U.S. Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs (Prolastin, Zemaira/Respreeza, Glassia, Aralast NP, Others), Gene Type (Type Pizz, Type Pims, Type Pimz, Others), Application (Lung Disease, Liver Disease), Population Type (Adults, Pediatric), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
U.S. Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Analysis and Size
In recent years, the incidence rate of Alpha-1 Antitrypsin Deficiency (AATD) has varied by population and region. AATD is considered a rare genetic disorder, and its prevalence is estimated to be approximately 1 in 2,000 to 1 in 5,000 individuals. However, the incidence can be much higher in certain populations.
Data Bridge Market Research analyzes that the U.S. alpha-1 antitrypsin deficiency (AATD) augmentation therapy market, which was USD 613.93 million in 2022, is likely to reach USD 1,223.30 million by 2030 and is expected to undergo a CAGR of 9.0% during the forecast period. “Prolastin” dominates the drugs segment of the market due to the growing demand for better methods for treatment in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
By Drugs (Prolastin, Zemaira/Respreeza, Glassia, Aralast NP, Others), Gene Type (Type Pizz, Type Pims, Type Pimz, Others), Application (Lung Disease, Liver Disease), Population Type (Adults, Pediatric), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Market Players Covered
|
Grifols, S.A. (Spain), CSL Limited (Australia), Kamada Pharmaceuticals (Israel), Takeda Pharmaceutical Company Limited (Japan), LFB BIOMEDICAMENTS (France), Arrowhead Pharmaceuticals, Inc. (U.S.), Mereo BioPharma Group plc (U.K.), Inhibrx, Inc. (U.S.), Centessa Pharmaceuticals (Z Factor) (U.S.), Intellia Therapeutics, Inc. (U.S.), Apic Bio (U.S.), Krystal Biotech (U.S.), Beam Therapeutics (U.S.), LOGICBIO THERAPEUTICS, INC. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Alpha-1 antitrypsin deficiency (AATD) is the condition that occurs when the liver fails to secrete a protein called alpha-1 antitrypsin that must be released into the blood-stream for various functions such as protecting tissues in the body from being attacked by body’s secreted enzymes. This genetic condition can progress to lung or liver diseases if left untreated. Most patients with this deficiency will either have less protein or do not produce the protein at all and therefore lose its function, leading to abnormal protein produced within the liver cells, causing liver injury.
U.S. Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics
Drivers
- Rise in Incidence and Prevalence of AATD
With the increase prevalence and incidence of AATD worldwide, there is an increase in the demand for effective therapy products which will increase in upcoming years. Therefore, rising incidences are expected to act as a driver for the growth of the market.
- Wide Range of Risks and Comorbidities with AATD
Another significant factor influencing the growth rate of the market is the wide range of risks and comorbidities with AATD. External factors such as smoking and alcohol consumption also affect severe outcomes directly. Progressive risk to live and lung health will aid the market.
- Improving Diagnostic Techniques for Genetic Disorders
Growing prevalence of alpha-1 antitrypsin deficiency (AATD) in various regions worldwide and various infections associated with it are expected to act as drivers for development in rare disease diagnostics. Accurate and reliable diagnosis can lead to better quality of life for patients and hence the growth of the market.
Opportunities
- Growing Research & Development Activities
The U.S. Food and Drug has approved several products currently available in the United States (U.S.) to treat emphysema in patients with AATD. However complete cure for alpha-1 antitrypsin deficiency (AATD) does not exist and hence gives way for new research and opportunity for development of better more effective therapies.
- Increased Awareness among Patients
The primary opportunity lies in increasing awareness about AATD. Many individuals with this condition remain undiagnosed, and there is room for education and outreach to both patients and healthcare providers, leading to earlier diagnosis and treatment.
Restraints/Challenges
- High Cost of Treatment
Augmentation therapy for AATD can be expensive. The cost of therapy and the potential financial burden on patients and healthcare systems can limit access to treatment.
- Variable Treatment Response
Responses to augmentation therapy can vary among patients. Some individuals may experience significant clinical benefit, while others may show limited improvement or no response.
This alpha-1 antitrypsin deficiency (AATD) augmentation therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In April 2019, CSL received the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial sizes for ZEMAIRA [Alpha1-Proteinase Inhibitor (Human)], its therapy for treating Alpha 1 Antitrypsin Deficiency (Alpha 1). This approval is significant for the Alpha 1 community as ZEMAIRA was previously available only in a 1-gram vial. This has helped the company to increase its revenue with this production
U.S. Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Scope
The alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is segmented on the basis of drugs, gene type, application, population type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Prolastin
- Aralast NP
- Zemaira/Respreeza
- Glassia
- Others
Gene Type
- Type PIMZ
- Type PIMS
- Type PIZZ
- Other
Population Type
- Adults
- Pediatric
End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The alpha-1 antitrypsin deficiency (AATD) augmentation therapy market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.
Competitive Landscape and Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Share Analysis
The alpha-1 antitrypsin deficiency (AATD) augmentation therapy market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market.
Some of the major players operating in the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market are:
- Grifols, S.A. (Spain)
- CSL Limited (Australia)
- Kamada Pharmaceuticals (Israel)
- Takeda Pharmaceutical Company Limited (Japan)
- LFB BIOMEDICAMENTS (France)
- Arrowhead Pharmaceuticals, Inc. (U.S.)
- Mereo BioPharma Group plc (U.K.)
- Inhibrx, Inc. (U.S.)
- Centessa Pharmaceuticals (Z Factor) (U.S.)
- Intellia Therapeutics, Inc. (U.S.)
- Apic Bio (U.S.)
- Krystal Biotech (U.S.)
- Beam Therapeutics (U.S.)
- LOGICBIO THERAPEUTICS, INC. (U.S.)
SKU-